Quantification of Epstein-Barr viral load and determination of a cut-off value to predict the risk of post-transplant lymohoproliferative disease in a renal transplant cohort

Post-transplant lymphoproliferative disorder (PTLD) is a life-threatening Epstein-Barr virus (EBV)-driven B-cell malignancy occurring in 1 to 3% of renal transplant patients.(1.2) Recently, EBV DNA quantification has become a useful tool for identifying patients at risk of developing PTLD.(3-5) However, studies on EBV load differ in design, methodology and type of patients.Univ Fed Sao Paulo, Hematol & Transfus Med Serv, UNIFESP EPM, Sao Paulo, BrazilLudwig Inst Canc Res, Sao Paulo, BrazilUFG, Dept Epidemiol, Goiania, Go, BrazilUniv Hosp Sao Paulo, UNIFESP EPM, Discipline Nefrol, Sao Paulo, BrazilHosp Rim & Hipertensao, Sao Paulo, BrazilUniv Fed Sao Paulo, Hematol & Transfus Med Serv, UNIFESP EPM, Sao Paulo, BrazilUniv Hosp Sao Paulo, UNIFESP EPM, Discipline Nefrol, Sao Paulo, BrazilWeb of Scienc